Clinical Trials Logo

Epidermolysis Bullosa clinical trials

View clinical trials related to Epidermolysis Bullosa.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06330324 Enrolling by invitation - Clinical trials for Epidermolysis Bullosa

Reproductive Options in Inherited Skin Diseases

REPRO-ISD
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the indications for prenatal diagnostics and preimplantation genetic testing for patients/couples affected by an inherited skin disease, and evaluate the clinical outcomes of these reproductive options. By providing a complete overview, the investigators aim to improve reproductive counselling for these patients/couples with a desire to have children. To achieve this, the investigators aim to retrospectively collect data from a cohort of patiens/couples affected by an inherited skin disease on a national level (in the Netherlands) and also an international level from various countries in Europe.

NCT ID: NCT05533866 Enrolling by invitation - Clinical trials for Epidermolysis Bullosa

Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution

Start date: February 6, 2023
Phase: Early Phase 1
Study type: Interventional

In this pilot study, APR-TD011 antimicrobial wound cleansing spray will be given to all enrolled patients with junctional EB (JEB) or dystrophic epidermolysis bullosa (DEB) with Staphylococcus aureus or Pseudomonas aeruginosa culture-positive wounds. The primary aim will be to evaluate the change in skin microbiome (S. aureus, P. aeruginosa, commensal organisms) before, during, after treatment. Subjects who are colonized by S. aureus or pseudomonas will be treated for 8 weeks, will stop the spray and return at 12 weeks (4 weeks without the spray), and then will be able to use the spray as desired in a 6-month period of open-label use, with further feedback collected.

NCT ID: NCT05288478 Enrolling by invitation - Clinical trials for Epidermolysis Bullosa

Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.

Start date: April 6, 2022
Phase: Phase 2
Study type: Interventional

Inherited Epidermolysis Bullosa (EB) is a disorder that causes skin fragility and blistering in skin and mucous membranes, including the mouth. Recurrent oral blisters and ulcer result in oral pain and discomfort. Dentoxol® is a mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. It has significant potential to reduce EB related oral symptoms. This study includes people living with Inherited Epidermolysis Bullosa aged 6 and above; and is aimed at determining the efficacy of two different dose regimens of Dentoxol mouthrinse in reducing oral symptoms.

NCT ID: NCT04727268 Enrolling by invitation - Clinical trials for Junctional Epidermolysis Bullosa

Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa

Start date: September 27, 2021
Phase:
Study type: Observational [Patient Registry]

This study will collect genetic and clinical information of junctional epidermolysis bullosa (JEB) patients. Computer analysis will be performed on genetic mutations found in these patients and this will be correlated with their clinical characteristics.